Neena M. Patil is CLO & VP at Jazz Pharmaceuticals plc (JAZZ). They have made 9 open-market trades across 1 company since 2022, most recently 2026-09-10.
CIK 0001783908
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| JAZZ | 47,671 | $10.0M |
| TFX | 3,716 | $485K |
| Total | $10.5M |
Shares reported on the most recent Form 4, priced at the 2026-09-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JAZZ | SELL · 10b5-1 | 2026-09-10 | 2026-09-14 | $240.94 | $289K | -3.2% | -14.1% | — |
| JAZZ | SELL · 10b5-1 | 2026-06-10 | 2026-06-12 | $231.83 | $278K | -1.5% | +3.2% | +4.7% |
| JAZZ | SELL · 10b5-1 | 2026-05-28 | 2026-06-01 | $236.97 | $282K | +1.9% | +2.5% | +8.3% |
| JAZZ | SELL | 2026-02-26 | 2026-03-02 | $191.56 | $10.7M | -3.1% | +1.2% | +25.0% |
| JAZZ | SELL | 2025-02-27 | 2025-03-03 | $144.87 | $551K | -2.4% | -9.3% | -22.3% |
| JAZZ | SELL | 2024-11-08 | 2024-11-13 | $123.41 | $457K | -2.1% | -3.1% | +2.3% |
| JAZZ | SELL | 2024-05-03 | 2024-05-07 | $109.65 | $548K | -2.6% | -5.0% | -0.3% |
| JAZZ | SELL · 10b5-1 | 2023-09-01 | 2023-09-06 | $144.25 | $216K | -3.3% | -5.8% | -11.3% |
| JAZZ | SELL | 2023-08-15 | 2023-08-17 | $139.59 | $209K | +4.9% | -3.4% | -8.5% |
| JAZZ | SELL | 2023-06-01 | 2023-06-05 | $127.98 | $400K | -0.8% | -4.9% | +6.9% |
| JAZZ | SELL | 2022-11-16 | 2022-11-18 | $142.34 | $999K | +6.4% | +6.3% | -0.6% |
| JAZZ | SELL | 2022-06-06 | 2022-06-08 | $152.15 | $152K | -2.0% | +4.1% | -0.8% |
| JAZZ | SELL | 2022-05-06 | 2022-05-10 | $153.92 | $46K | +4.0% | +3.7% | +7.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.